Objectives Interventions to prevent childhood respiratory syncytial virus (RSV) disease are
limited and costly. New interventions are in advanced stages of development and could be …

Background Respiratory syncytial virus (RSV) causes a substantial burden of acute lower
respiratory infection in children under 5 years, particularly in low-and middle-income …

Background Respiratory syncytial virus (RSV) imposes a substantial burden on pediatric
hospital capacity in Europe. Promising prophylactic interventions against RSV including …

Background Respiratory syncytial virus (RSV) frequently causes acute lower respiratory
infection in children under 5, representing a high burden in Gavi-eligible countries (mostly …

Background Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in
young children. A number of mathematical models have been used to assess the cost …

Background New prevention strategies for respiratory syncytial virus (RSV) are emerging,
but it is unclear if they will be cost-effective in low-and middle-income countries. We …

Background New monoclonal antibodies (mAbs) and vaccines against RSV with promising
efficacy and protection duration are expected to be available in the near future. We …

Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5–10 years. The most efficient way …

Background Two new products for preventing Respiratory Syncytial Virus (RSV) in young
children have been licensed: a single-dose long-acting monoclonal antibody (la-mAB) and a …

Background Every winter, respiratory syncytial virus (RSV) disease results in thousands of
cases in Norwegian children under 5 years of age. We aim to assess the RSV-related …